NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
13.00
+0.31 (2.44%)
At close: Sep 18, 2025, 4:00 PM EDT
13.01
+0.01 (0.04%)
After-hours: Sep 18, 2025, 7:44 PM EDT
NovoCure Revenue
NovoCure had revenue of $158.81M in the quarter ending June 30, 2025, with 5.62% growth. This brings the company's revenue in the last twelve months to $630.16M, up 14.58% year-over-year. In the year 2024, NovoCure had annual revenue of $605.22M with 18.82% growth.
Revenue (ttm)
$630.16M
Revenue Growth
+14.58%
P/S Ratio
2.26
Revenue / Employee
$423,495
Employees
1,488
Market Cap
1.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 605.22M | 95.88M | 18.82% |
| Dec 31, 2023 | 509.34M | -28.50M | -5.30% |
| Dec 31, 2022 | 537.84M | 2.81M | 0.53% |
| Dec 31, 2021 | 535.03M | 40.66M | 8.23% |
| Dec 31, 2020 | 494.37M | 143.05M | 40.72% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
NVCR News
- 3 days ago - Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC) - Business Wire
- 8 days ago - NovoCure Limited (NVCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 21 days ago - Novocure Announces Upcoming Investor Events - Business Wire
- 24 days ago - Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain - Business Wire
- 4 weeks ago - Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer - Business Wire
- 7 weeks ago - NovoCure's Wearable Oncology Edge And Compelling Valuation - Seeking Alpha
- 7 weeks ago - Top 3 Health Care Stocks That May Explode In July - Benzinga
- 7 weeks ago - NovoCure Limited (NVCR) Q2 2025 Earnings Call Transcript - Seeking Alpha